Strategies to improve posttransplant immunity - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 133

[20] Le Blanc K, Barrett AJ, Schaffer M, Hagglund H, Ljungman P, Ringden O, et al. Lympho-
cyte recovery is a major determinant of outcome after matched unrelated myeloabla-
tive transplantation for myelogenous malignancies. Biol Blood Marrow Transplant
2009;15(9):1108-15. Epub 2009/08/08.
[21] Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, van den Brink MR, et al. Direct
evidence for new T-cell generation by patients after either T-cell-depleted or unmodi-
fied allogeneic hematopoietic stem cell transplantations. Blood 2002;100(6):2235-42.
[22] Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic
interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood
2001;98(5):1601-6. Epub 2001/08/25.
[23] Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative
stem cell transplantation. Blood 2000;96(7):2419-25.
[24] Peggs KS. Role of MabCampath in allogeneic transplantation. Ann Hematol
2004;83(Suppl. 1):S66-8. Epub 2004/05/06.
[25] Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, et al. Impact of
in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical
sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitu-
tion. Blood 2010;116(16):3080-8. Epub 2010/07/01.
[26] Juliusson G, Theorin N, Karlsson K, Frodin U, Malm C. Subcutaneous alemtuzumab
vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath
dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant
2006;37(5):503-10. Epub 2006/01/18.
[27] Fehse N, Fehse B, Kroger N, Zabelina T, Freiberger P, Kruger W, et al. Influence of anti-
thymocyte globulin as part of the conditioning regimen on immune reconstitution
following matched related bone marrow transplantation. J Hematother Stem Cell Res
2003;12(2):237-42. Epub 2003/06/14.
[28] Meijer E, Bloem AC, Dekker AW, Verdonck LF. Effect of antithymocyte globulin on quan-
titative immune recovery and graft-versus-host disease after partially T-cell-depleted
bone marrow transplantation: a comparison between recipients of matched related and
matched unrelated donor grafts. Transplantation 2003;75(11):1910-3. Epub 2003/06/18.
[29] Terasako K, Sato K, Sato M, Kimura S, Nakasone H, Okuda S, et al. The effect of
different ATG preparations on immune recovery after allogeneic hematopoietic stem
cell transplantation for severe aplastic anemia. Hematology 2010;15(3):165-9. Epub
2010/06/19.
[30] Clave E, Busson M, Douay C, Peffault de Latour R, Berrou J, Rabian C, et al. Acute
graft-versus-host disease transiently impairs thymic output in young patients after
allogeneic hematopoietic stem cell transplantation. Blood 2009;113(25):6477-84. Epub
2009/03/05.
[31] Olkinuora H, von Willebrand E, Kantele JM, Vainio O, Talvensaari K, Saarinen-Pihkala
U, et al. The impact of early viral infections and graft-versus-host disease on im-
mune reconstitution following paediatric stem cell transplantation. Scand J Immunol
2011;73(6):586-93. Epub 2011/02/18.
[32] Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, et al.
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute
graft-vs-host disease. Bone Marrow Transplant 2007;40(5):481-6. Epub 2007/07/10.
[33] Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refrac-
tory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol
2001;112(3):820-3.
[34] Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-
refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood
Marrow Transplant 2002;8(3):155-60.
[35] McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ, et al. Treatment of
steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J
Hematother Stem Cell Res 2000;9(3):367-74.
[36] Remberger M, Ringden O, Aschan J, Ljungman P, Lonnqvist B, Markling L. Long-term
follow-up of a randomized trial comparing T-cell depletion with a combination of
methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Trans-
plant Proc 1994;26(3):1829-30.
[37] Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, et al. Treatment of steroid-
resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow
Transplant 2001;27(10):1059-64.
[38] Krenger W, Hollander GA. The immunopathology of thymic GVHD. Semin Immuno-
pathol 2008;30(4):439-56. Epub 2008/11/01.
[39] Heim LR, Martinez C, Good RA. Cause of homologous disease. Nature 1967;
214(5083):26-9. Epub 1967/04/01.

135